General
Preferred name
TENELIGLIPTIN
Synonyms
MP513 ()
MP-513 ()
Teneligliptin hydrobromide ()
Teneligliptin (hydrobromide) ()
Teneligliptin (hydrobromide hydrate) ()
MP-513 (hydrobromide) ()
MP-513 (hydrobromide hydrate) ()
Teneligliptine ()
Teneligliptina ()
P&D ID
PD012726
CAS
760937-92-6
906093-29-6
1572583-29-9
Tags
available
drug
Approved by
PMDA
First approval
2012
Drug indication
Type-2 diabetes
diabetes mellitus
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Teneligliptin is a long-acting, orally bioavailable dipeptidyl peptidase 4 (DPP-4) inhibitor . It was developed for clinical potential in type 2 diabetes management, to improve glycemic control. In addition to their anti-diabetic activity, DPP4 inhibitors may have renal and cardiovascular protective effects.
(GtoPdb)
DESCRIPTION
Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].
PRICE
39
DESCRIPTION
Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].
DESCRIPTION
Teneligliptin (MP-513) is a novel dipeptidyl peptidase 4 (DPP IV) inhibitor for the treatment of type 2 diabetes mellitus with hypoglycemic activity for the study of obesity and diabetes.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Other bioactive compounds
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
426.22
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
1.57
TPSA
56.64
Fraction CSP3
0.55
Chiral centers
2.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
DPP-4
DPP4
AMPK
Apoptosis
Dipeptidyl Peptidase
Interleukin Related
JNK
NF-κB
NOD-like Receptor (NLR)
p38 MAPK
Reactive Oxygen Species (ROS)
Toll-like Receptor (TLR)
Reactive Oxygen Species
Indication
diabetes mellitus
MOA
dipeptidyl peptidase inhibitor
Pathway
Proteases/Proteasome
Epigenetics
Immunology/Inflammation
MAPK/ERK Pathway
Metabolic Enzyme/Protease
PI3K/Akt/mTOR
NF-¦ÊB
Source data
